Ultimately, I mean to replace the standard of care, we do need a phase 3 trial, RCT, that head-to-head compares IO plus a novel ADC versus perioperative IO chemotherapy. And before we embark on such a large trial, usually we start with a phase two design. And in our study, we hypothesized that the IO plus cetuximab would lead to a 20% improvement in pCR rate compared to the pCR rate in the KEYNOTE 671 study...
Ultimately, I mean to replace the standard of care, we do need a phase 3 trial, RCT, that head-to-head compares IO plus a novel ADC versus perioperative IO chemotherapy. And before we embark on such a large trial, usually we start with a phase two design. And in our study, we hypothesized that the IO plus cetuximab would lead to a 20% improvement in pCR rate compared to the pCR rate in the KEYNOTE 671 study. So we hypothesized that there’s an improvement from 18% pCR to 38% pCR, and then with one-sided alpha 0.05 power 0.8, we calculated the sample size of 37 in this regard. However, after achieving a signal, we do need an RCT to validate this concept.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.